Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

      Interim Management Statement - 3 months to 30 June 2012 (unaudited)      

Worldwide Healthcare Trust PLC invests worldwide in a diversified portfolio of 
shares in pharmaceutical and biotechnology companies and related securities in 
 the healthcare sector with the objective of achieving a high level of capital 
                                    growth.                                    

The three month period ended 30 June 2012 was a positive one for the Company
due, in part, to strong returns from portfolio holdings in Questcor
Pharmaceuticals following reports of strong sales of its multiple sclerosis
treatment Acthar and also from Onyx Pharmaceuticals following a positive vote
from a U.S. Food & Drug Administration Panel for the approval of its drug
Carfilzomib for the treatment of advanced Myeloma. Over the three-month period,
the Company's net asset value total return was +5.8% and the share price total
return was +4.9%, compared to a rise of 3.1% in the Company's benchmark, the
MSCI World Health Care Index measured on a total return basis in sterling
terms. In the period from 30 June 2012 to 1 August 2012, the Company's net
asset value total return was +1.4% and the share price total return was +1.7%,
compared to a rise of 2.7% in the Company's benchmark.

During the three month period and to the date of this report 2,225,369 shares
were repurchased for treasury by the Company. On 18 July 2012 the Company
cancelled all of the 2,941,518 shares then held in treasury. At the date of
this report the Company has 192,437 shares held in treasury.

31 July 2012 was the last opportunity for holders of the Company's subscription
shares to exercise their subscription rights at an exercise price of 638p. The
exercise price is now 699p where it will remain until the expiry date of the
subscription shares on 31 July 2014. The next subscription date is 31 October
2012. During the period under review and to the date of this report a total of
4,670,680 new shares were issued as a result of holders of subscription shares
exercising their subscription rights.

The Company paid an increased interim dividend of 17.5p per share (2011: 15.0p
per share) on 6 July 2012.

The Board has decided that, in future, the Company will declare two interim
dividends per year, one at the half-year stage and one shortly after the
year-end. It is therefore expected that in respect of the year ending 31 March
2013 a first interim dividend will be declared in November 2012 and a second
interim dividend will be declared in May 2013.

At the Company's Annual General Meeting, held on 17 July 2012, all of the
resolutions were passed. Professor Duncan Geddes retired from the Board at the
conclusion of the Annual General Meeting.

Trust Characteristics

                            30 June 2012             31 March 2012             
                                                                               
Number of holdings          58                       67                        
                                                                               
Net assets (£m)             399.9                    382.3                     
                                                                               
Net yield                   2.1%                     1.9%                      
                                                                               
Gearing (AIC basis)         115                      117                       
                                                                               
Share price (p)             815.50                   795.00                    
                                                                               
NAV (p) -undiluted          914.42                   887.47                    
                                                                               
NAV (p) diluted: sub shares 886.62                   852.15                    
                                                                               
NAV (p) - fully diluted for 883.18                   851.14                    
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
Discount (undiluted)        10.8%                    10.4%                     
                                                                               
Discount (diluted - sub     8.0%                     6.7%                      
shares)                                                                        
                                                                               
Discount (fully diluted)    7.7%                     6.6%                      
                                                                               
Subscription share price    168.00                   133.50                    
(p)                                                                            

Source: Frostrow Capital LLP

10 Largest Investments

Name                       % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2012           at 31 March 2012          
                                                                               
Merck & Co                 5.3                       3.3                       
                                                                               
Roche                      5.1                       4.7                       
                                                                               
Pfizer                     5.1                                  5.3            
                                                                               
Abbott Laboratories        4.2                       3.3                       
                                                                               
Bristol-Myers Squibb       4.2                       2.3                       
                                                                               
Sanofi                     3.5                       3.8                       
                                                                               
Mitsubishi Tanabe Pharma   3.4                       3.3                       
                                                                               
Gilead Sciences            3.0                       2.9                       
                                                                               
Incyte Genomics            2.7                       2.3                       
                                                                               
Novartis                   2.6                       4.3                       
                                                                               
                           39.1                      35.5                      

Source: Frostrow Capital LLP

Sector Analysis

                           % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2012           at 31 March 2012          
                                                                               
Large capitalisation       63.7                      65.2                      
                                                                               
Small capitalisation       36.3                      34.8                      
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP

Geographical Analysis

                           % of                      % of                      
                                                                               
                           portfolio                 portfolio                 
                                                                               
                           at 30 June 2012           at 31 March 2012          
                                                                               
North America              63.3                      64.6                      
                                                                               
Europe                     20.2                      20.9                      
                                                                               
Asia                       9.0                       8.3                       
                                                                               
Emerging Markets           7.5                       6.2                       
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +4.9            +10.8           +63.3           +80.3          
                                                                               
NAV Fully       +5.8            +10.2           +65.8           +81.7          
diluted                                                                        
                                                                               
Benchmark*      +3.1            +8.2            +57.9           +60.8          

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Bloomberg and Thomson Reuters

* With effect from 1 October 2010, the performance of the Company is measured
against the MSCI World Health Care Index measured on a total return basis in
sterling terms. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index on a total return basis
in sterling terms. Historic data, therefore, consists of a blended figure
containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares

SEDOL- 0338530

ISIN - GB0003385308

Bloomberg - WWH LN

EPIC - WWH

Subscription Shares

SEDOL - B3VMCB0

ISIN - GB00B3VMCB07

Bloomberg - WWHS LN

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

3 August 2012